Genetic association studies in digestive system malignancies

Anticancer Research

Volumn 27, Issue 5 B, 2007, Pages 3577-3587

  Tsigris, Christos ^a   Chatzitheofylaktou, Agape ^a   Xiromeritis, Constantinos ^a   Nikiteas, Nikolaus ^a   Yannopoulos, Athanasios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Colorectal cancer; DNA polymorphisms; Gastric cancer; Genetic association; Head and neck cancer; Review

Indexed keywords

BLOOD CLOTTING FACTOR; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE; DNA; HLA ANTIGEN; MATRIX METALLOPROTEINASE;

CANCER CLASSIFICATION; CARCINOGENESIS; DIET; DIGESTIVE SYSTEM CANCER; DNA POLYMORPHISM; ENVIRONMENTAL FACTOR; GENE MUTATION; GENETIC ASSOCIATION; HEREDITY; HUMAN; IMMUNE SYSTEM; MULTIFACTORIAL INHERITANCE; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ANIMALS; DIET; DIGESTIVE SYSTEM NEOPLASMS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNE SYSTEM; POLYMORPHISM, GENETIC; SIGNAL TRANSDUCTION;

EID: 35348989236     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (121)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55(2): 74-108, 2005.
2. Silverman S Jr: Demographics and occurrence of oral and pharyngeal cancers. The outcomes, the trends, the challenge. J Am Dent Assoc 132: 7S-11S, 2001.
3. Dixon K and Kopras E: Genetic alterations and DNA repair in human carcinogenesis. Semin Cancer Biol 14(6): 441-448, 2004.
4. Tiret L: Gene-environment interaction: a central concept in multifactorial diseases. Proc Nutr Soc 61(4): 457-463, 2002.
5. Wünsch Fiiho V and Zago MA: Modern cancer epidemiological research: genetic polymorphisms and environment. Rev Saude Publica 39(3): 490-497, 2005.
6. Barber M, Fitzgerald RC and Caldas C: Familial gastric cancer - aetiology and pathogenesis. Best Pract Res Clin Gastroenterol 20(4): 721-734, 2006.
7. Kemp Z, Thirlwell C, Sieber O, Silver A and Tomlinson I: An update on the genetics of colorectal cancer. Hum Mol Genet 13(2): 177-185, 2004.
8. Turnbull C and Hodgson S: Genetic predisposition to cancer. Clin Med 5(5): 491-498, 2005.
9. El-Omar EM: Role of host genes in sporadic gastric cancer. Best Pract Res Clin Gastroenterol 20(4): 675-686, 2006.
10. Cooper DN, Nussbaum RL and Krawczak M: Proposed guidelines for papers describing DNA polymorphism-disease associations. Hum Genet 110(3): 207-208, 2002.
11. Bateman AC and Howell WM: Human leukocyte antigens and cancer: is it in our genes? J Pathol 188(3): 231-236, 1999.
12. Howell WM and Rose-Zerilli MJ: Cytokine gene polymorphisms, cancer susceptibility, and prognosis. J Nutr 137: 194-199, 2007.
13. Ye S: Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biol 19(7): 623-629, 2000.
14. Ahmed FE: Gene-gene, gene-environment and multiple interactions in colorectal cancer. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 24(1): 1-101, 2006.
15. Macarthur M, Hold GL and El-Omar EM: Inflammation and Cancer II. Role of chronic inflammation and cytokine gene polymorphisms in the pathogenesis of gastrointestinal malignancy. Am J Physiol Gastrointest Liver Physiol 286(4): 515-520, 2004.
16. Howell WM, Calder PC and Grimble RF: Gene polymorphisms, inflammatory diseases and cancer. Proc Nutr Soc 61(4): 447-456, 2002.
17. Azuma T, Ito S, Sato F, Yamazaki Y, Miyaji H, Ito Y, Suto H, Kuriyama M, Kato T and Kohli Y: The role of the HLA-DQA1 gene in resistance to atrophic gastritis and gastric adenocarcinoma induced by Helicobacter pylori infection. Cancer 82(6): 1013-1018, 1998.
18. Magnusson PKE, Enroth H, Eriksson I, Held M, Nyrén O, Engstrand L, Hansson LE and Gyllensten UB: Gastric cancer and human leukocyte antigen: distinct DQ and DR alleles are associated with development of gastric cancer and infection by Helicobacter pylori. Cancer Res 61(6): 2684-2689, 2001.
19. Lee JE, Lowy AM, Thompson WA, Lu M, Loflin PT, Skibber JM, Evans DB, Curley SA, Mansfield PF and Reveille JD: Association of gastric adenocarcinoma with the HLA class II gene DQB10301. Gastroenterology 111(2): 426-432, 1996.
20. Salazar-Onfray F, López MN and Mendoza-Naranjo A: Paradoxical effects of cytokines in tumor immune surveillance and tumor immune escape. Cytokine Growth Factor Rev 18(1-2): 171-182, 2007.
21. Dranoff G: Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer 4(1): 11-22, 2004.
22. Vairaktaris E, Serefoglou Z, Yapijakis C, Vassiliou S, Derka S, Nkenke E, Vylliotis A, Ragos V, Neukam FW and Patsouris E: The interleukin-1 beta polymorphism +3953 C/T is not associated with risk for oral cancer. Anticancer Res in press, 2007.
23. Tsai MH, Chen WC, Tsai CH, Hang LW and Tsai FJ: Interleukin-4 gene, but not the interleukin-1 beta gene polymorphism, is associated with oral cancer. J Clin Lab Anal 19(3): 93-98, 2005.
24. Macarthur M, Sharp L, Hold GL, Little J and El-Omar EM: The role of cytokine gene polymorphisms in colorectal cancer and their interaction with aspirin use in the northeast of Scotland. Cancer Epidemiol Biomarkers Prev 14(7): 1613-1618, 2005.
25. Savage SA, Abnet CC, Haque K, Mark SD, Qiao YL, Dong ZW, Dawsey SM, Taylor PR and Chanock SJ: Polymorphisms in interleukin-2, -6, and -10 are not associated with gastric cardia or esophageal cancer in a high-risk Chinese population. Cancer Epidemiol Biomarkers Prev 13(9): 1547-1549, 2004.
26. Togawa S, Joh T, Itoh M, Katsuda N, Ito H, Matsuo K, Tajima K and Hamajima N: Interleukin-2 gene polymorphisms associated with increased risk of gastric atrophy from Helicobacter pylori infection. Helicobacter 10(3): 172-178, 2005.
27. Vairaktaris E, Yannopoulos A, Vassiliou S, Serefoglou Z, Vylliotis A, Nkenke E, Critselis E, Avgoustidis D, Yapijakis C, Neukam FW and Patsouris E: Strong association of interleukin-4 (-590 C/T) polymorphism with increased risk for oral squamous cell carcinoma in Europeans. Oral Surg Oral Med Oral Pathol Oral Radiol Endod, in press, 2007.
28. Landi S, Bottari F, Gemignani F, Gioia-Patricola L, Guino E, Osorio A, de Oca J, Capella G, Canzian F and Moreno V; Bellvitge Colorectal Cancer Study Group: Interleukin-4 and interleukin-4 receptor polymorphisms and colorectal cancer risk. Eur J Cancer 43(4): 762-768, 2007.
29. Vairaktaris E, Yiannopoulos A, Vylliotis A, Yapijakis C, Derka S, Vassiliou S, Nkenke E, Serefoglou Z, Ragos V, Tsigris C, Vorris E, Critselis E, Avgoustidis D, Neukam FW and Patsouris E: Strong association of interleukin-6 -174 G>C promoter polymorphism with increased risk of oral cancer. Int J Biol Markers 21(4): 246-250, 2006.
30. Landi S, Moreno V, Gioia-Patricola L, Guino E, Navarro M, de Oca J, Capella G and Canzian F; Bellvitge Colorectal Cancer Study Group: Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res 63(13): 3560-3566, 2003.
31. Theodoropoulos G, Papaconstantinou I, Felekouras E, Nikiteas N, Karakitsos P, Panoussopoulos D, Lazaris ACh, Patsouris E, Bramis J and Gazouli M: Relation between common polymorphisms in genes related to inflammatory response and colorectal cancer. World J Gastroenterol 12(31): 5037-5043, 2006.
32. Vairaktaris E, Yapijakis C, Serefoglou Z, Derka S, Vassiliou S, Nkenke E, Vylliotis A, Wiltfang J, Avgoustidis D, Critselis E, Neukam FW and Patsouris E: The interleukin-8 (-251A/T) polymorphism is associated with increased risk for oral squamous cell carcinoma. Eur J Surg Oncol 33(4): 504-507, 2007.
33. Savage SA, Abnet CC, Mark SD, Qiao YL, Dong ZW, Dawsey SM, Taylor PR and Chanock SJ: Variants of the IL8 and IL8RB genes and risk for gastric cardia adenocarcinoma and esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 13(12): 2251-2257, 2004.
34. Gunter MJ, Canzian F, Landi S, Chanock SJ, Sinha R and Rothman N: Inflammation-related gene polymorphisms and colorectal adenoma. Cancer Epidemiol Biomarkers Prev 15(6): 1126-1131, 2006.
35. Pratesi C, Bortolin MT, Bidoli E, Tedeschi R, Vaccher E, Dolcetti R, Guidoboni M, Franchin G, Barzan L, Zanussi S, Caruso C and De Paoli P: Interleukin-10 and interleukin-18 promoter polymorphisms in an Italian cohort of patients with undifferentiated carcinoma of nasopharyngeal type. Cancer Immunol Immunother 55(1): 23-30, 2006.
36. Crivello A, Giacalone A, Vaglica M, Scola L, Forte GI, Macaluso MC, Raimondi C, Di Noto L, Bongiovanni A, Accardo A, Candore G, Palmeri L, Verna R, Caruso C, Lio D and Palmeri S: Regulatory cytokine gene polymorphisms and risk of colorectal carcinoma. Ann N Y Acad Sci 1089: 98-103, 2006.
37. Guo W, Wang N, Wang YM, Li Y, Wen DG, Chen ZF, He YT and Zhang JH: Interleukin-10 -1082 promoter polymorphism is not associated with susceptibility to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma in a population of high-incidence region of north China. World J Gastroenterol 11(6): 858-862, 2005.
38. Wu MS, Huang SP, Chang YT, Shun CT, Chang MC, Lin MT, Wang HP and Lin JT: Tumor necrosis factor-alpha and interleukin-10 promoter polymorphisms in Epstein-Barr virus-associated gastric carcinoma. J Infect Dis 185(1): 106-109, 2002.
39. Helminen M, Lahdenpohja N and Hurme M: Polymorphism of the interleukin-10 gene is associated with susceptibility to Epsteine Barr virus infection. J Infect Dis 180(2): 496-499, 1999.
40. Vairaktaris E, Yapijakis C, Serefoglou Z, Derka S, Vassiliou S, Nkenke E, Vylliotis A, Spyridonidou S, Tsigris C, Neukam FW and Patsouris E: Gene expression polymorphism of interleukin-10 is associated with risk for oral squamous carcinoma. Hum Immunol, in press.
41. Wei YS, Zhu YH, Du B, Yang ZH, Liang WB, Lv ML, Kuang XH, Tai SH, Zhao Y and Zhang L: Association of transforming growth factor-beta1 gene polymorphisms with genetic susceptibility to nasopharyngeal carcinoma. Clin Chim Acta 380(1-2): 165-169, 2007.
42. Jin G, Wang L, Chen W, Hu Z, Zhou Y, Tan Y, Wang J, Hua Z, Ding W, Shen J, Zhang Z, Wang X, Xu Y and Shen H: Variant alleles of TGFB1 and TGFBR2 are associated with a decreased risk of gastric cancer in a Chinese population. Int J Cancer 120(6): 1330-1335, 2007.
43. Liu CJ, Wong YK, Chang KW, Chang HC, Liu HF and Lee YJ: Tumor necrosis factor-alpha promoter polymorphism is associated with susceptibility to oral squamous cell carcinoma. J Oral Pathol Med 34(10): 608-612, 2005.
44. Chiu CJ, Chiang CP, Chang ML, Chen HM, Hahn U, Hsieh LL, Kuo YS and Chen CJ: Association between genetic polymorphism of tumor necrosis factor-alpha and risk of oral submucous fibrosis, a pre-cancerous condition of oral cancer. J Dent Res 80(12): 2055-2059, 2001.
45. Yapijakis C, Vairaktaris E, Serefoglou Z, Vylliotis A, Ries J, Nkenke E, Kessler P, Derka S, Vassiliou S and Neukam FW: Association of tumor necrosis factor alpha -308 G/A and beta 252 G/A polymorphisms with increased risk for oral cancer. Int J Biol Markers, in press.
46. Ho SY, Wang YJ, Huang PC, Tsai ST, Chen CH, Chen HH, Chang CJ and Guo HR: Evaluation of the associations between the single nucleotide polymorphisms of the promoter region of the tumor necrosis factor-alpha gene and nasopharyngeal carcinoma. J Chin Med Assoc 69(8): 351-357, 2006.
47. Guo W, Wang N, Li Y and Zhang JH: Polymorphisms in tumor necrosis factor genes and susceptibility to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma in a population of high incidence region of North China. Chin Med J (Engl) 118(22): 1870-1878, 2005.
48. Correa P, Piazuelo MB and Camargo MC: The future of gastric cancer prevention. Gastric Cancer 7(1): 9-16, 2004.
49. De Jong MM, Nolte IM, te Meerman GJ, van der Graaf WT, de Vries EG, Sijmons RH, Hofstra RM and Kleibeuker JH: Low-penetrance genes and their involvement in colorectal cancer susceptibility. Cancer Epidemiol Biomarkers Prev 11: 1332-1352, 2002.
50. Vairaktaris E, Serefoglou Charalambus Z, Vassiliou S, Nkenke E, Yapijakis C, Chatzitheofylaktou A, Vylliotis A, Spyridonidou S, Neukam FW and Patsouris E: No association between the interleukin-18 -607 A/C gene polymorphism and risk for oral cancer. Anticancer Res, in press.
51. Segal S and Hill AV: Genetic susceptibility to infectious disease. Trends Microbiol 11(9): 445-448, 2003.
52. Chen X and Yang CS: Esophageal adenocarcinoma: a review and perspectives on the mechanism of carcinogenesis and chemoprevention. Carcinogenesis 22(8): 1119-1129, 2001.
53. Vairaktaris E, Yapijakis C, Derka S, Serefoglou Z, Vassiliou S, Nkenke E, Ragos V, Vylliotis A, Spyridonidou S, Tsigris C, Yannopoulos A, Tesseromatis C, Neukam FW and Patsouris E: Association of matrix metalloproteinase-1 (-1607 1G/2G) polymorphism with increased risk for oral squamous cell carcinoma. Anticancer Res 27(1A): 459-464, 2007.
54. O-charoenrat P, Leksrisakul P and Sangruchi S: A functional polymorphism in the matrix metalloproteinase-1 gene promoter is associated with susceptibility and aggressiveness of head and neck cancer. Int J Cancer 118(10): 2548-2553, 2006.
55. Vairaktaris E, Yapijakis C, Vasiliou S, Derka S, Nkenke E, Serefoglou Z, Vorris E, Vylliotis A, Ragos V, Neukam F and Patsouris E: Association of-1171 promoter polymorphism of matrix metalloproteinase-3 with increased risk for oral cancer. Anticancer Res, in press, 2007.
56. Lin SC, Chung MY, Huang JW, Shieh TM, Liu CJ and Chang KW: Correlation between functional genotypes in the matrix metalloproteinases-1 promoter and risk of oral squamous cell carcinomas. J Oral Pathol Med 33(6): 323-326, 2004.
57. Hashimoto T, Uchida K, Okayama N, Imate Y, Suehiro Y, Hamanaka Y, Ueyama Y, Shinozaki F, Yamashita H and Hinoda Y: Association of matrix metalloproteinase (MMP)-1 promoter polymorphism with head and neck squamous cell carcinoma. Cancer Lett 211(1): 19-24, 2004.
58. Jin X, Kuang G, Wei LZ, Li Y, Wang R, Guo W, Wang N, Fang SM, Wen DG, Chen ZF and Zhang JH: No association of the matrix metalloproteinase 1 promoter polymorphism with susceptibility to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma in northern China. World J Gastroenterol 11(16): 2385-2389, 2005.
59. Yasui W, Oue N, Aung PP, Matsumura S, Shutoh M and Nakayama H: Molecular-pathological prognostic factors of gastric cancer: a review. Gastric Cancer 8(2): 86-94, 2005.
60. Lièvre A, Milet J, Carayol J, Le Corre D, Milan C, Pariente A, Nalet B, Lafon J, Faivre J, Bonithon-Kopp C, Olschwang S, Bonaiti-Pellié C and Laurent-Puig P; members of the ANGH group: Genetic polymorphisms of MMP1, MMP3 and MMP7 gene promoter and risk of colorectal adenoma. BMC Cancer 6: 270, 2006.
61. Xu E, Lai M, Lu B, Xing X and Huang Q: No association between the polymorphisms in matrix metalloproteinase-1 and matrix metalloproteinase-3 promoter regions and colorectal cancer in Chinese. Dis Colon Rectum 49(9): 1439-1444, 2006.
62. O-Charoenrat P and Khantapura P: The role of genetic polymorphisms in the promoters of the matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 genes in head and neck cancer. Oral Oncol 42(3): 257-267, 2006.
63. Lin SC, Lo SS, Liu CJ, Chung MY, Huang JW and Chang KW: Functional genotype in matrix metalloproteinases-2 promoter is a risk factor for oral carcinogenesis. J Oral Pathol Med 33(7): 405-409, 2004.
64. Zhang XM, Miao XP, Xiong P, Yu CY, Tan W, Qu SN, Sun T, Zhou YF and Lin DX: Association of functional polymorphisms in matrix metalloproteinase-2 (MMP-2) and MMP-9 genes with risk of gastric cancer in a Chinese population. Ai Zheng 23(11): 1233-1237, 2004. [Article in Chinese]
65. Xu EP, Huang Q, Lu BJ, Xing XM and Lai MD: The correlation between polymorphisms of matrix metalloproteinase-2 and -9 genes and colorectal cancer of Chinese patients. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 23(1): 78-81, 2006 (in Chinese).
66. Xu E, Lai M, Lv B, Xing X, Huang Q and Xia X: A single nucleotide polymorphism in the matrix metalloproteinase-2 promoter is associated with colorectal cancer. Biochem Biophys Res Commun 324(3): 999-1003, 2004.
67. Zhang J, Jin X, Fang S, Li Y, Wang R, Guo W, Wang N, Wang Y, Wen D, Wei L, Kuang G and Dong Z: The functional SNP in the matrix metalloproteinase-3 promoter modifies susceptibility and lymphatic metastasis in esophageal squamous cell carcinoma but not in gastric cardiac adenocarcinoma. Carcinogenesis 25(12): 2519-2524, 2004.
68. Vairaktaris E, Vassiliou S, Nkenke E, Serefoglou Z, Derka S, Tsigris C, Vylliotis A, Yapijakis C, Neukam FW and Patsouris E: A metalloproteinase-9 polymorphism which affects its expression is associated with increased risk for oral squamous cell carcinoma. Eur J Surg Oncol, in press, 2007.
69. Xu E, Xia X, Lu B, Xing X, Huang Q, Ma Y, Wang W and Lai M: Association of matrix metalloproteinase-2 and -9 promoter polymorphisms with colorectal cancer in Chinese. Mol Carcinog, in press, 2007.
70. Elander N, Söderkvist P and Fransén K: Matrix metalloproteinase (MMP) -1, -2, -3 and -9 promoter polymorphisms in colorectal cancer. Anticancer Res 26(1B): 791-796, 2006.
71. Vairaktaris E, Yapijakis C, Yiannopoulos A, Vassiliou S, Serefoglou Z, Vylliotis A, Nkenke E, Derka S, Critselis E, Avgoustidis D, Neukam FW and Patsouris E: Strong association of the tissue inhibitor of metalloproteinase- 2 polymorphism with an increased risk of oral squamous cell carcinoma in Europeans. Oncol Rep 17(4): 963-968, 2007.
72. Wu CY, Wu MS, Chen YJ, Chen CJ, Chen HP, Shun CT, Chen GH, Huang SP and Lin JT: Clinicopathological significance of MMP-2 and TIMP-2 genotypes in gastric cancer. Eur J Cancer 43(4): 799-808, 2007.
73. Larsen M, Artym W, Green JA and Yamada KM: The matrix reorganized: extracellular matrix remodeling and integrin signaling. Curr Opin Cell Biol 18(5): 463-471, 2006.
74. Nagase H, Visse R and Murphy G: Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 69(3): 562-573, 2006.
75. Rosenthal EL and Matrisian LM: Matrix metalloproteases in head and neck cancer. Head Neck 28(7): 639-648, 2006.
76. Katoh T, Kaneko S, Kohshi K, Munaka M, Kitagawa K, Kunugita N, Ikemura K and Kawamoto T: Genetic polymorphisms of tobacco- and alcohol-related metabolizing enzymes and oral cavity cancer. Int J Cancer 83(5): 606-609, 1999.
77. Lu XM, Zhang YM, Lin RY, Arzi G, Wang X, Zhang YL, Zhang Y, Wang Y and Wen H: Relationship between genetic polymorphisms of metabolizing enzymes CYP2E1, GSTM1 and Kazakh's esophageal squamous cell cancer in Xinjiang, China. World J Gastroenterol 11(24): 3651-3654, 2005.
78. Chen SY, Liu TY, Shun CT, Wu MS, Lu TH, Lin JT, Sheu JC, Santella RM and Chen CJ: Modification effects of GSTM1, GSTT1 and CYP2E1 polymorphisms on associations between raw salted food and incomplete intestinal metaplasia in a high-risk area of stomach cancer. Int J Cancer 108(4): 606-612, 2004.
79. Reszka E, Wasowicz W and Gromadzinska J: Genetic polymorphism of xenobiotic metabolising enzymes, diet and cancer susceptibility. Br J Nutr 96(4): 609-619, 2006.
80. Le Marchand L, Donlon T, Seifried A and Wilkens LR: Red meat intake, CYP2E1 genetic polymorphisms, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev 11(10 Pt 1): 1019-1024, 2002.
81. Sweeney C, Coles BF, Nowell S, Lang NP and Kadlubar FF: Novel markers of susceptibility to carcinogens in diet: associations with colorectal cancer. Toxicology 181-182: 83-87, 2002.
82. Buch SC, Notani PN and Bhisey RA: Polymorphism at GSTM1, GSTM3 and GSTT1 gene loci and susceptibility to oral cancer in an Indian population. Carcinogenesis 23(5): 803-807, 2002.
83. Casson AG, Zheng Z, Porter GA and Guernsey DL: Genetic polymorphisms of microsomal epoxide hydroxylase and glutathione S-transferases M1, T1 and P1, interactions with smoking, and risk for esophageal (Barrett) adenocarcinoma. Cancer Detect Prev 30(5): 423-431, 2006.
84. Jain M, Kumar S, Rastogi N, Lal P, Ghoshal UC, Tiwari A, Pant MC, Baiq MQ and Mittal B: GSTT1, GSTM1 and GSTP1 genetic polymorphisms and interaction with tobacco, alcohol and occupational exposure in esophageal cancer patients from North India. Cancer Lett 242(1): 60-67, 2006.
85. Lai KC, Chen WC, Tsai FJ, Li SY, Chou MC and Jeng LB: Glutathione S-transferase M1 gene null genotype and gastric cancer risk in Taiwan. Hepatogastroenterology 52(66): 1916-1919, 2005.
86. Tiemersma EW, Kampman E, Bueno de Mesquita HB, Bunschoten A, van Schothorst EM, Kok FJ and Kromhout D: Meat consumption, cigarette smoking, and genetic susceptibility in the etiology of colorectal cancer: results from a Dutch prospective study. Cancer Causes Control 13(4): 383-393, 2002.
87. Martínez C, Martín F, Fernández JM, García-Martín E, Sastre J, Díaz-Rubio M, Agúndez JA and Ladero JM: Glutathione S-transferases mu 1, theta 1, pi 1, alpha 1 and mu 3 genetic polymorphisms and the risk of colorectal and gastric cancers in humans. Pharmacogenomics 7(5): 711-718, 2006.
88. Sikdar N, Paul RR and Roy B: Glutathione S-transferase M3 (A/A) genotype as a risk factor for oral cancer and leukoplakia among Indian tobacco smokers. Int J Cancer 109(1): 95-101, 2004.
89. Tamer L, Ates NA, Ates C, Ercan B, Elipek T, Yildirim H, Camdeviren H, Atik U and Aydin S: Glutathione S-transferase M1, T1 and P1 genetic polymorphisms, cigarette smoking and gastric cancer risk. Cell Biochem Funct 23(4): 267-272, 2005.
90. Turner F, Smith G, Sachse C, Lightfoot T, Garner RC, Wolf CR, Forman D, Bishop DT and Barrett JH: Vegetable, fruit and meat consumption and potential risk modifying genes in relation to colorectal cancer. Int J Cancer 112(2): 259-264, 2004.
91. Seow A, Yuan JM, Sun CL, Van Den Berg D, Lee HP and Yu MC: Dietary isothiocyanates, glutathione S-transferase polymorphisms and colorectal cancer risk in the Singapore Chinese Health Study. Carcinogenesis 23(12): 2055-2061, 2002.
92. Wang Y, Guo W, He Y, Chen Z, Wen D, Zhang X, Wang N, Li Y, Ge H and Zhang J: Association of MTHFR C677T and SHMT(1) C1420T with susceptibility to ESCC and GCA in a high incident region of Northern China. Cancer Causes Control 18(2): 143-152, 2007.
93. Graziano F, Kawakami K, Ruzzo A, Watanabe G, Santini D, Pizzagalli F, Bisonni R, Mari D, Floriani I, Catalano V, Silva R, Tonini G, Torri V, Giustini L and Magnani M: Methylenetetrahydrofolate reductase 677C/T gene polymorphism, gastric cancer susceptibility and genomic DNA hypomethylation in an at-risk Italian population. Int J Cancer 118(3): 628-632, 2006.
94. Shen H, Newmann AS, Hu Z, Zhang Z, Xu Y, Wang L, Hu X, Guo J, Wang X and Wei Q: Methylenetetrahydrofolate reductase polymorphisms/haplotypes and risk of gastric cancer: a case-control analysis in China. Oncol Rep 13(2): 355-360, 2005.
95. Vairaktaris E, Yapijakis C, Kessler P, Vylliotis A, Ries J, Wiltfang J, Vassiliou S, Derka S and Neukam FW: Methylenetetrahydrofolate reductase polymorphism and minor increase of risk for oral cancer. J Cancer Res Clin Oncol 132(4): 219-222, 2006.
96. Larsson SC, Giovannucci E and Wolk A: Folate intake, MTHFR polymorphisms, and risk of esophageal, gastric, and pancreatic cancer: a meta-analysis. Gastroenterology 131(4): 1271-1283, 2006.
97. Zeybek U, Yaylim I, Yilmaz H, Agaçhan B, Ergen A, Arikan S, Bayrak S and Isbir T: Methylenetetrahydrofolate reductase C677T polymorphism in patients with gastric and colorectal cancer. Cell Biochem Funct 25(4): 419-422, 2006.
98. Weng YR, Sun DF, Fang JY, Gu WQ and Zhu HY: Folate levels in mucosal tissue but not methylenetetrahydrofolate reductase polymorphisms are associated with gastric carcinogenesis. World J Gastroenterol 12(47): 7591-7597, 2006.
99. Powers HJ: Interaction among folate, riboflavin, genotype, and cancer, with reference to colorectal and cervical cancer. J Nutr 135(12 Suppl): 2960-2966, 2005.
100. Kono S and Chen K: Genetic polymorphisms of methylenetetrahydrofolate reductase and colorectal cancer and adenoma. Cancer Sci 96(9): 535-542, 2005.
101. Vairaktaris E, Yapijakis C, Tsigris C, Vassiliou S, Derka S, Nkenke E, Spyridonidou S, Vylliotis A, Vorris E, Ragos V, Neukam F and Patsouris E: Association of angiotensin-converting enzyme gene insertion/deletion polymorphism with increased risk for oral cancer. Acta Oncol, in press, 2007.
102. Chung FM, Yang YH, Chen CH, Lin CC and Shieh TY: Angiotensin- converting enzyme gene insertion/deletion polymorphism is associated with risk of oral precancerous lesion in betel quid chewers. Br J Cancer 93(5): 602-606, 2005.
103. Goto Y, Ando T, Nishio K, Ishida Y, Kawai S, Goto H and Hamajima N: The ACE gene polymorphism is associated with the incidence of gastric cancer among H. pylori seropositive subjects with atrophic gastritis. Asian Pac J Cancer Prev 6(4): 464-467, 2005.
104. Ebert MP, Lendeckel U, Westphal S, Dierkes J, Glas J, Folwaczny C, Roessner A, Stolte M, Malfertheiner P and Röcken C: The angiotensin I-converting enzyme gene insertion/deletion polymorphism is linked to early gastric cancer. Cancer Epidemiol Biomarkers Prev 14(12): 2987-2989, 2005.
105. Sugimoto M, Furuta T, Shirai N, Ikuma M, Sugimura H and Hishida A: Influences of chymase and angiotensin I-converting enzyme gene polymorphisms on gastric cancer risks in Japan. Cancer Epidemiol Biomarkers Prev 15(10): 1929-1934, 2006.
106. Vairaktaris E, Yapijakis C, Wiltfang J, Ries J, Vylliotis A, Derka S, Vasiliou S and Neukam FW: Are factor V and prothrombin mutations associated with increased risk of oral cancer? Anticancer Res 25(3c): 2561-2565, 2005.
107. Mózsik G, Rumi G, Dömötör A, Figler M, Gasztonyi B, Papp E, Pár A, Pár G, Belágyi J, Matus Z and Melegh B: Involvement of serum retinoids and Leiden mutation in patients with esophageal, gastric, liver, pancreatic, and colorectal cancers in Hungary. World J Gastroenterol 11(48): 7646-7650, 2005.
108. Battistelli S, Stefanoni M, Genovese A, Vittoria A, Cappelli R and Roviello F: Prevalence of factor V Leiden and prothrombin G20210A in patients with gastric cancer. World J Gastroenterol 12(26): 4179-4180, 2006.
109. Paspatis GA, Sfyridaki A, Papanikolaou N, Triantafyliou K, Livadiotaki A, Kapsoritakis A and Lydataki N: Resistance to activated protein C, factor V leiden and the prothrombin G20210A variant in patients with colorectal cancer. Pathophysiol Haemost Thromb 32(1): 2-7, 2002.
110. Vairaktaris E, Yapijakis C, Derka S, Vassiliou S, Serefoglou Z, Vylliotis A, Wiltfang J, Springer I, Nkenke E, Kessler P and Neukam FW: Association of platelet glycoprotein Ia polymorphism with minor increase of risk for oral cancer. Eur J Surg Oncol 32(4): 455-457, 2006.
111. Vairaktaris E, Yapijakis C, Serefoglou Z, Vylliotis A, Ries J, Nkenke E, Wiltfang J, Derka S, Vassiliou S, Springer I, Kessler P and Neukam FW: Plasminogen activator inhibitor-1 polymorphism is associated with increased risk for oral cancer. Oral Oncol 42(9): 888-892, 2006.
112. Wu MS, Huang SP, Chang YT, Lin MT, Shun CT, Chang MC, Wang HP, Chen CJ and Lin JT: Association of the -160 C - > a promoter polymorphism of E-cadherin gene with gastric carcinoma risk. Cancer 94(5): 1443-1448, 2002.
113. Pharoah PD, Oliveira C, Machado JC, Keller G, Vogelsang H, Laux H, Becker KF, Hahn H, Paproski SM, Brown LA, Caldas C and Huntsman D: CDH1 c-160a promotor polymorphism is not associated with risk of stomach cancer. Int J Cancer 101(2): 196-197, 2002.
114. Liao SY, Zeng ZR, Leung WK, Zhou SZ, Chen B, Sung JJ and Hu PJ: Peroxisome proliferator-activated receptor-gamma Pro12Ala polymorphism, Helicobacter pylori infection and noncardia gastric carcinoma in Chinese. Aliment Pharmacol Ther 23(2): 289-294, 2006.
115. Vairaktaris E, Loukeri S, Vassiliou S, Nkenke E, Spyridonidou S, Vylliotis A, Papacosta V, Lazaris A, Agrogiannis G, Yapijakis C, Perrea D and Patsouris E: EGFR and c-Jun exhibit the same pattern of expression and increase gradually during the progress of oral oncogenesis. In Vivo, in press, 2007.
116. Vairaktaris E, Goutzanis L, Nkenke E, Spyridonidou S, Vassiliou S, Derka S, Vylliotis A, Yapijakis C, Lazaris A, Strantzias P and Patsouris E: Diabetes does not influence oral oncogenesis through the pathway of fibroblast growth factor receptors. In Vivo 21: 623-628, 2007.
117. Vairaktaris E, Goutzanis L, Vassiliou S, Spyridonidou S, Nkenke E, Papageorgiou G, Strantzias P, Lazaris A, Yapijakis C and Patsouris E: Enhancement of erbB2 and erbB3 expression during oral oncogenesis in diabetic rats. J Cancer Res Clin Oncol, in press.
118. Vairaktaris E, Ragos V, Yapijakis C, Derka S, Vassiliou S, Nkenke E, Yannopoulos A, Spyridonidou S, Vylliotis A, Papakosta V, Loukeri S, Lazaris A, Tesseromatis C, Tsigris C and Patsouris E: FGFR-2 and -3 play an important role in initial stages of oral oncogenesis. Anticancer Res 26(6B): 4217-4222, 2006.
119. Yapijakis C, Vairaktaris E, Vassiliou S, Vylliotis A, Nkenke E, Nixon AM, Derka S, Spyridonidou S, Vorris E, Neukam F and Patsouris E: The low VEGF production allele of the +936C/T polymorphism is strongly associated with increased risk for oral cancer. J Cancer Res Clin Oncol, in press, 2007.
120. Tzanakis N, Gazouli M, Rallis G, Giannopoulos G, Papaconstantinou I, Theodoropoulos G, Pikoulis E, Tsigris C, Karakitsos P, Peros G and Nikiteas N: Vascular endothelial growth factor polymorphisms in gastric cancer development, prognosis, and survival. J Surg Oncol 94(7): 624-630, 2006.
121. Wu GY, Wang XM, Keese M, Hasenberg T and Sturm JW: Association between vascular endothelial growth factor gene 936 T/C polymorphism and colorectal cancer together with anastomotic leakage. Zhonghua Wai Ke Za Zhi 44(21): 1505-1507, 2006 (in Chinese).